Switching to Adempas (riociguat) is a potential therapeutic option for patients with pulmonary arterial…
Articles by Patricia Inácio, PhD
A key milestone has been achieved in the development of Inventiva’s IVA337, an anti-fibrotic drug for treating systemic sclerosis (SSc),…
Activation of certain immune cells in scleroderma (SSc) may be linked to infection with Epstein-Barr virus (EBV), researchers showed. The…
Levels of the cytokine CXCl4 in the bloodstream drop sharply in response to immunosuppressive therapy, and are associated with improved…
Activating a class of nuclear receptors, called peroxisome proliferator-activated receptors (PPARs), with the drug IVA337 eased fibrosis in an animal model…
Researchers found that increased levels of Th-17 cytokines are associated with interstitial lung disease in patients with systemic sclerosis (SSc).
Samumed has recently presented promising results on investigative product SM04755, a small molecule that modulates cells’ Wnt pathway, showing the drug’s potential…
A new topical medicine, called SM04755, significantly decreased and even reversed fibrosis and inflammation in in vitro and in vivo mouse…
Corbus Pharmaceuticals recently announced that its Phase 2 clinical trial assessing the drug Resunab as a potential treatment for diffuse cutaneous…
In the lung’s extracellular matrix (ECM) — observed in both cultured cells from systemic sclerosis patients and a mouse model — the protein netrin-1 was seen to regulate the…